Regeneron Change To Inventory vs Begin Period Cash Flow Analysis

REGN Stock

USD 716.68 2.21 0.31%

Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Change To Inventory and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Change To Inventory vs Begin Period Cash Flow

Change To Inventory vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Change To Inventory account and Begin Period Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Regeneron Pharmaceuticals' Change To Inventory and Begin Period Cash Flow is -0.67. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Change To Inventory and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of Regeneron Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Change To Inventory i.e., Regeneron Pharmaceuticals' Change To Inventory and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.67

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 26th of December 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.97	1.0	0.95	-0.06	0.99	0.97	0.93	-0.25	0.96	0.98	0.15	0.95	0.26	-0.66	0.97	0.98	0.83	0.86	0.94	0.98	0.63	0.99	0.93	0.98	0.58
Total Current Liabilities	0.97		0.96	0.94	-0.03	0.95	0.99	0.84	-0.32	0.98	0.98	0.2	0.95	0.4	-0.66	0.99	0.99	0.73	0.92	0.89	0.99	0.72	0.97	0.83	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.93	-0.09	0.99	0.95	0.94	-0.26	0.95	0.96	0.13	0.92	0.22	-0.67	0.95	0.97	0.85	0.83	0.95	0.96	0.6	0.99	0.94	0.97	0.56
Property Plant And Equipment Net	0.95	0.94	0.93		-0.16	0.9	0.93	0.88	-0.16	0.9	0.95	0.31	0.96	0.33	-0.45	0.96	0.93	0.69	0.84	0.83	0.95	0.71	0.97	0.82	0.96	0.78
Net Debt	-0.06	-0.03	-0.09	-0.16		0.0	-0.1	-0.01	0.13	-0.14	-0.01	-0.17	0.08	0.03	-0.49	0.02	-0.09	0.03	0.28	-0.16	-0.08	-0.08	-0.1	0.01	-0.06	-0.4
Retained Earnings	0.99	0.95	0.99	0.9	0.0		0.94	0.93	-0.28	0.95	0.96	0.05	0.91	0.21	-0.75	0.95	0.97	0.87	0.85	0.95	0.95	0.57	0.97	0.95	0.96	0.48
Cash	0.97	0.99	0.95	0.93	-0.1	0.94		0.82	-0.32	0.98	0.98	0.23	0.93	0.41	-0.62	0.98	0.99	0.71	0.9	0.89	0.98	0.72	0.95	0.82	0.97	0.54
Non Current Assets Total	0.93	0.84	0.94	0.88	-0.01	0.93	0.82		-0.09	0.8	0.86	0.07	0.88	0.09	-0.62	0.87	0.84	0.9	0.73	0.87	0.86	0.46	0.93	0.98	0.89	0.6
Non Currrent Assets Other	-0.25	-0.32	-0.26	-0.16	0.13	-0.28	-0.32	-0.09		-0.4	-0.22	-0.04	-0.07	0.03	0.27	-0.21	-0.33	-0.42	-0.22	-0.27	-0.23	0.06	-0.24	-0.17	-0.24	-0.01
Cash And Short Term Investments	0.96	0.98	0.95	0.9	-0.14	0.95	0.98	0.8	-0.4		0.97	0.18	0.89	0.34	-0.63	0.95	0.99	0.73	0.85	0.92	0.97	0.68	0.95	0.82	0.95	0.5
Net Receivables	0.98	0.98	0.96	0.95	-0.01	0.96	0.98	0.86	-0.22	0.97		0.22	0.97	0.32	-0.65	0.99	0.99	0.71	0.91	0.9	0.98	0.71	0.97	0.85	0.97	0.56
Common Stock Shares Outstanding	0.15	0.2	0.13	0.31	-0.17	0.05	0.23	0.07	-0.04	0.18	0.22		0.28	0.27	0.37	0.24	0.19	-0.07	0.21	0.06	0.21	0.26	0.2	-0.02	0.16	0.47
Non Current Liabilities Total	0.95	0.95	0.92	0.96	0.08	0.91	0.93	0.88	-0.07	0.89	0.97	0.28		0.4	-0.59	0.99	0.93	0.67	0.93	0.81	0.96	0.74	0.95	0.83	0.96	0.65
Other Current Assets	0.26	0.4	0.22	0.33	0.03	0.21	0.41	0.09	0.03	0.34	0.32	0.27	0.4		-0.09	0.4	0.34	-0.08	0.47	0.1	0.42	0.73	0.23	0.05	0.38	0.2
Other Stockholder Equity	-0.66	-0.66	-0.67	-0.45	-0.49	-0.75	-0.62	-0.62	0.27	-0.63	-0.65	0.37	-0.59	-0.09		-0.63	-0.65	-0.71	-0.7	-0.66	-0.61	-0.29	-0.6	-0.71	-0.63	0.11
Total Liab	0.97	0.99	0.95	0.96	0.02	0.95	0.98	0.87	-0.21	0.95	0.99	0.24	0.99	0.4	-0.63		0.97	0.71	0.94	0.86	0.99	0.74	0.97	0.84	0.98	0.61
Total Current Assets	0.98	0.99	0.97	0.93	-0.09	0.97	0.99	0.84	-0.33	0.99	0.99	0.19	0.93	0.34	-0.65	0.97		0.75	0.88	0.92	0.98	0.69	0.97	0.85	0.97	0.53
Intangible Assets	0.83	0.73	0.85	0.69	0.03	0.87	0.71	0.9	-0.42	0.73	0.71	-0.07	0.67	-0.08	-0.71	0.71	0.75		0.61	0.82	0.72	0.21	0.81	0.94	0.77	0.37
Short Long Term Debt Total	0.86	0.92	0.83	0.84	0.28	0.85	0.9	0.73	-0.22	0.85	0.91	0.21	0.93	0.47	-0.7	0.94	0.88	0.61		0.69	0.9	0.72	0.85	0.71	0.89	0.42
Other Current Liab	0.94	0.89	0.95	0.83	-0.16	0.95	0.89	0.87	-0.27	0.92	0.9	0.06	0.81	0.1	-0.66	0.86	0.92	0.82	0.69		0.88	0.46	0.93	0.91	0.88	0.45
Accounts Payable	0.98	0.99	0.96	0.95	-0.08	0.95	0.98	0.86	-0.23	0.97	0.98	0.21	0.96	0.42	-0.61	0.99	0.98	0.72	0.9	0.88		0.78	0.97	0.84	0.99	0.59
Short Term Debt	0.63	0.72	0.6	0.71	-0.08	0.57	0.72	0.46	0.06	0.68	0.71	0.26	0.74	0.73	-0.29	0.74	0.69	0.21	0.72	0.46	0.78		0.63	0.41	0.71	0.46
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.1	0.97	0.95	0.93	-0.24	0.95	0.97	0.2	0.95	0.23	-0.6	0.97	0.97	0.81	0.85	0.93	0.97	0.63		0.91	0.97	0.65
Short Term Investments	0.93	0.83	0.94	0.82	0.01	0.95	0.82	0.98	-0.17	0.82	0.85	-0.02	0.83	0.05	-0.71	0.84	0.85	0.94	0.71	0.91	0.84	0.41	0.91		0.88	0.47
Inventory	0.98	0.98	0.97	0.96	-0.06	0.96	0.97	0.89	-0.24	0.95	0.97	0.16	0.96	0.38	-0.63	0.98	0.97	0.77	0.89	0.88	0.99	0.71	0.97	0.88		0.6
Other Liab	0.58	0.56	0.56	0.78	-0.4	0.48	0.54	0.6	-0.01	0.5	0.56	0.47	0.65	0.2	0.11	0.61	0.53	0.37	0.42	0.45	0.59	0.46	0.65	0.47	0.6

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Total Current Liabilities	1.8B	2.8B	3.5B	3.8B	3.4B	3.6B
Total Stockholder Equity	11.1B	11.0B	18.8B	22.7B	26.0B	27.3B
Property Plant And Equipment Net	2.9B	3.2B	3.5B	3.8B	4.2B	4.4B
Net Debt	(903.9M)	502M	(185.9M)	(404.5M)	(27.1M)	(28.5M)
Retained Earnings	7.4B	10.9B	19.0B	23.3B	27.3B	28.6B
Cash	1.6B	2.2B	2.9B	3.1B	2.7B	2.9B
Non Current Assets Total	4.2B	4.4B	4.9B	7.1B	13.6B	14.3B
Non Currrent Assets Other	531.8M	328.9M	555.2M	(4.7B)	366.1M	384.4M
Cash And Short Term Investments	6.5B	6.7B	12.5B	14.3B	10.8B	11.4B
Net Receivables	2.7B	4.1B	6.0B	5.3B	5.7B	6.0B
Common Stock Shares Outstanding	114.6M	115.1M	112.2M	113.5M	113.7M	75.4M
Liabilities And Stockholders Equity	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Non Current Liabilities Total	1.9B	3.3B	3.2B	2.7B	3.7B	3.9B
Other Current Assets	959.3M	1.2B	664.8M	411.2M	386.6M	197.8M
Other Stockholder Equity	3.7B	102.9M	(173.4M)	(404M)	(1.2B)	(1.1B)
Total Liab	3.7B	6.1B	6.7B	6.6B	7.1B	7.5B
Total Current Assets	10.6B	12.8B	20.5B	22.1B	19.5B	20.5B
Short Long Term Debt Total	713.9M	3.6B	2.7B	2.7B	2.7B	2.8B
Other Current Liab	781.1M	122.4M	2.2B	2.1B	2.4B	2.5B
Accounts Payable	418.1M	475.5M	564M	589.2M	606.6M	636.9M
Property Plant And Equipment Gross	2.9B	3.2B	4.9B	5.4B	6.1B	6.4B
Accumulated Other Comprehensive Income	21.1M	29.3M	(26.2M)	(238.8M)	(80.9M)	(76.9M)
Short Term Investments	1.6B	1.4B	2.8B	4.6B	8.1B	8.5B
Inventory	1.4B	1.9B	2.0B	2.4B	2.6B	2.7B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	910.6M	913.3M	2.8B	555.2M	747.6M	0.0
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	591.7M	577.7M	442M	547.7M	458.9M	481.8M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B

Pair Trading with Regeneron Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Regeneron Stock

0.93	ME	23Andme Holding	Pair Corr
0.87	VALN	Valneva SE ADR	Pair Corr

Moving against Regeneron Stock

0.9	VCEL	Vericel Corp Ord	Pair Corr
0.84	VCYT	Veracyte	Pair Corr
0.77	SABSW	SAB Biotherapeutics	Pair Corr
0.68	DRUG	Bright Minds Biosciences	Pair Corr
0.65	DRTS	Alpha Tau Medical	Pair Corr

The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.

The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.298

Earnings Share

40.44

Revenue Per Share

128.691

Quarterly Revenue Growth

0.106

Return On Assets

0.0741

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Change To Inventory vs Begin Period Cash Flow Analysis

Change To Inventory vs Begin Period Cash Flow

Change To Inventory vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Change To Inventory

Begin Period Cash Flow

Regeneron Pharmaceuticals fundamental ratios Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals fundamental ratios Accounts

Pair Trading with Regeneron Pharmaceuticals

Moving together with Regeneron Stock

Moving against Regeneron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Current Liabilities

Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Investments	- 0.71	Other Stockholder Equity
Intangible Assets	- 0.71	Other Stockholder Equity
Short Long Term Debt Total	- 0.7	Other Stockholder Equity
Other Stockholder Equity	- 0.67	Total Stockholder Equity
Other Current Liab	- 0.66	Other Stockholder Equity